Orion-yhtyma Oy

Forendo Pharma Ltd

Hormos Medical Oy Ltd.

Cygnus Therapeutic Systems

Farmos Group Ltd.

Other

Farmos-yhtyma Oy

Alko Ltd.

Quatrx Pharmaceuticals

Hormors Medical Oy Ltd.

Risto Arvo Sakari Lammintausta

Orion-yhtyma Oy, a Finnish Body Corporate

Risto A Lammintausta

Lauri V Kangas

Arto J Karjalainen

Arja Marketta Kalapudas

Pasi Koskimies

Leena Hirvelä

Harry Gosta Jalonen

Maire Eloranta

Reino O Pelkonen

Raimo E Virtanen

Mikko Unkila

Marja-Liisa Sodervall

Jarmo Sakari Salonen

Gary W Cleary

Risto Santti

Tomi Streng

Kaija Halonen

Marjo Hakola

Aire Maria Laine

Donald R Wilson

Kenneth J Colley

Antti Talo

Ewen MacDonald

Alexander James Bridges

Kauko O Kurkela

Arto Olavi Urtti

Arja L Karjalainen

John D Sinclair

Kalervo Väänänen

Rochelle Hanley

Harry Scheinin

Marja-Liisa S&ouml;dervall

Pirkko Härkönen

Matti A Lahde

Marja-Liisa Södervall

Sakari A Nieminen

Mauno M Airaksinen

Antti Valjakka

Riitta A Miettinen

Pirkko H&auml;rk&ouml;nen

Jouni S Sirvio

Paavo Riekkinen, Jr

Kalervo Vaan&auml;nen

Paavo J Riekkinen

Robert L Zerbe

Hannu U Jalonen

Terttu M Heikkila

Stuart Dombey

Maria-Liisa Sodervall

Aire Marja Laine

Eija Kalso

Thomas Yorio

Ewen Macdonald

Raimo Virtanen

Arto Urtti

Leena HirvelÄ

The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. 

Prodrugs of 17&#x3b2;-HSD1-inhibitors

A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.

Methods for the treatment of erectile dysfunction using fispemifene

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Prodrugs of 17.BETA.-HSD1-inhibitors

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.

Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17&#x3b2;-hydroxysteroid dehydrogenase

The invention provides novel selective estrogen receptor modulator compounds of the general formula:wherein R1 and R2, which are the same or different are

Triphenylalkene derivatives and their use as selective estrogen receptor modulators

This invention relates to the use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ration (DATER) as well as to a method for the treatment of detrusor urethral sphincter dyssnergia (DUSD) in men.

Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents

The invention relates to a method for the treatment of detrusor urethral sphincter dyssynergia in men, said method comprising administering to the patient an effective amount of an aromatase inhibitor. The invention also concerns a method for the treatment of decreased androgen to estrogen ratio in men, said method comprising administering to the patient an effective amount of an aromatase inhibitor.

Use of an aromatase inhibitor in the treatment of decreased androgen to

##STR1## New compounds of formula (I) wherein R.sub.1 is H, CH.sub.3, OCH.sub.3, NO.sub.2, NH.sub.2, CN, CF.sub.3, CHF.sub.2, CH.sub.2 F or halogen, R.sub.2 is a heterocyclyl radical selected from 1-imidazolyl, triazolyl, tetrazolyl, pyrazolyl, pyrimidinyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl, R.sub.3 is H or OH, R.sub.4 is H, R.sub.5 is H or OH; or R.sub.4 is H and R.sub.3 and R.sub.5 combined form a bond; or R.sub.3 is H and R.sub.4 and R.sub.5 combined form .dbd.O; R.sub.6 is methylene, ethylene, --CHOH--, --CH.sub.2 --CHOH--, --CHOH--CH.sub.2 --, --CH.dbd.CH-- or --C(.dbd.O)--; or R.sub.4 is H and R.sub.5 and R.sub.6 combined is .dbd.CH-- or .dbd.CH--CH.sub.2 --; stereoisomers thereof and non-toxic pharmaceutically acceptable acid addition salts thereof exhibit selective aromatase inhibiting properties, compared with their desmolase inhibiting properties. The compounds of the invention are valuable in the treatment of estrogen dependent diseases, e.g. breast cancer or benign prostatic hyperplasia (BPH).

Selective aromatase inhibiting compounds

Drug formulations for parenteral use

Selective aromatase inhibiting 4(5)-imidazoles

Pharmaceutical compositions containing 4-substituted imidazoles to be

Growing community of inventors

Turku, Finland

Risto A Lammintausta